Biogen Idec, Inc. (Massachusetts) (BIIB) Data At Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio And Commitment To Advancing Patient Care
9/3/2014 9:04:27 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will present more than 90 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for multiple sclerosis (MS), as well as the company’s programs to address unmet needs in patient management, at the sixth Triennial Joint Meeting of ACTRIMS and ECTRIMS in Boston, September 10 – 13, 2014. The breadth and volume of data exemplify Biogen Idec’s industry-leading expertise in research and development, comprehensive product portfolio, and enduring commitment to the MS community. ACTRIMS-ECTRIMS is the joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS).
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by